Researchers at the Massachusetts Institute of Technology and Recursion Pharmaceuticals Inc. have released an open-source AI model that can predict the binding strength of small molecules as well as structures of proteins and biomolecular complexes. The model, which is called Boltz-2 and was released by the research team on the developer platform Github on June 6, addresses a major bottleneck in drug discovery with its improved ability to predict binding strengths. Read More

In progressive fibrotic diseases, which can occur in nearly all organs, myofibroblasts are activated to differentiate into proliferating fibroblastic cells that express genes that lead to deposition of extracellular matrix. The factors driving myofibroblast activation appear to be varied and complex, ranging from mechanical insults to inflammation, infection and cancer. Read More

Researchers from Guangdong Pharmaceutical University and collaborators reported the discovery of [I], a novel FABP/PPAR multiple modulator aimed at the treatment of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a complex liver disease with limited treatment options. Read More

Myosin Therapeutics Inc. has obtained IND clearance by the FDA for MT-125. A phase I study will evaluate MT-125 in combination with standard-of-care radiation in patients with newly diagnosed IDH wild type, MGMT unmethylated glioblastoma. Read More

Alys Pharmaceuticals Inc. has submitted a clinical trial application (CTA) to Germany’s Paul-Ehrlich-Institut (PEI) to initiate a phase I/Ib study of ALY-301 in healthy volunteers and patients with cold urticaria, a subtype of chronic inducible urticaria. Read More

In accordance with the publishing schedule, BioWorld Science was not published on Monday, June 9, 2025. Read More

Nuevocor Pte. Ltd. has obtained IND clearance by the FDA for NVC-001, an AAV-based gene therapy. Read More

Researchers have investigated the role of the voltage-dependent potassium channel Kv1.3 in vivo in a murine model of ethanol-exposed alcohol-related liver disease (ALD). Read More

An Eli Lilly & Co. patent describes new relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of diabetes, stroke, atherosclerosis and more. Read More

Solve FSHD and Modalis Therapeutics Corp. have established a strategic collaboration to develop an innovative therapy for facioscapulohumeral muscular dystrophy (FSHD). Read More

Persistent activation of the stimulator of interferon genes (STING), resulting from aberrant metabolism or mutations in STING1, can lead to inflammatory damage and autoimmune diseases. Therefore, inhibiting STING activity may offer therapeutic potential for treating these disorders. Read More

Astrazeneca AB has reported the identification of 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH; MASH), among others. Read More

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented 5-[2,7-diazaspiro[3.5]nonan-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives acting as matrix metalloproteinase-9, (MMP-9) inhibitors potentially useful for the treatment of dry eye. Read More

Acute myeloid leukemia (AML) is the most prevalent hematological malignancy. Despite advances in the field, about 60% of patients with AML do not survive >5 years. It is an urgent need to identify novel therapeutic targets for managing AML. Read More

Work at Emory University has led to the development of peptidomimetic compounds acting as protease (viral) inhibitors reported to be useful for the treatment of viral infections. Read More

Gastric cancer, which is the fifth most frequent cancer globally and the third most frequent cause of cancer-related deaths, can be managed relatively well with existing therapies. Advanced gastric cancer, in contrast, is more difficult to manage. Read More

Hepatocellular carcinoma is the most frequent form of primary liver cancer, and most patients are diagnosed when the disease is already advanced and therefore prognosis is poor despite available treatments. Understanding what contributes to the malignancy may help develop effective treatments. Read More

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer. Read More

Additional early-stage research and drug discovery news in brief, from: Addex Therapeutics, Artelo Biosciences, Seyltx, Spur Therapeutics, Sionna Therapeutics, Telomir Pharmaceuticals. Read More